Natural Alternatives International and CarnoSyn® Brands Publish Clinical Research Demonstrating TriBsyn™ Delivering Exceptional Bioavailability, Increased Efficiency and Paresthesia Elimination
05 Marzo 2025 - 9:20PM
Natural Alternatives International, Inc. (NAI) and CarnoSyn® Brands
today announced the publication of positive clinical trial results
in the journal Food Hydrocolloids for Health showing that TriBsyn™
supplementation led to significantly greater bioavailability and
efficiency of beta-alanine along with the elimination of
paresthesia, a common beta-alanine side effect.
Study Highlights:
- TriBsyn™ is an encapsulated
low-dose β-alanine complex.
- TriBsyn™ increased plasma β-alanine
4.5-fold compared to conventional β-alanine.
- TriBsyn™ achieved high plasma
concentrations without the sensation of paresthesia.
TriBsyn™ is a carnosine booster derived from
CarnoSyn® beta-alanine and formulated using proprietary Hydro
Oleo technology. This patent-pending formulation provides higher
bioavailability and higher potency, enabling efficacious dosages at
lower volumes while effectively eliminating paresthesia. The
advanced formulation enables absorption through multiple pathways,
including direct cellular uptake and traditional gastrointestinal
routes, allowing for superior delivery at both the cellular and
systemic levels. Adequate availability of beta-alanine is critical
for maintaining muscle and promoting cognitive well-being.
Efficacious doses of beta-alanine are often associated with
harmless but generally uncomfortable symptoms of paresthesia,
discouraging adherence to supplementation.
This study aimed to evaluate the
bioavailability, pharmacokinetics, and tolerability of a 400 mg
Hydro Oleo encapsulated beta-alanine complex (TriBsyn™)
specifically designed to reduce paresthesia. A randomized,
double-blind, single-dose, three-treatment, three-way crossover
oral bioavailability study was conducted in healthy older adults
under fasting conditions. The study compared TriBsyn™ with low (400
mg) and high (1200 mg) doses of conventional beta-alanine. TriBsyn™
(400 mg) achieved a nearly 4.5-fold and 1.3-fold increase in
circulating beta-alanine plasma concentrations compared to 400 mg
and 1200 mg of conventional beta-alanine, respectively.
Using metrics such as the Visual Analogue Score
(VAS) and Qualitative Light Symptoms Inventory (QLSI), sensory side
effects were assessed. No paresthesia or adverse effects were
reported in the TriBsyn™ group, while the conventional beta-alanine
groups exhibited increasing paresthesia with dose. TriBsyn™ (400 mg
beta-alanine) recorded a VAS score of 0.62 (indicating almost
absent symptoms), whereas conventional β-alanine (400 mg) and
conventional β-alanine (1200 mg) scored 2.02 and 4.01 respectively.
These results highlight the reduced sensory discomfort in the
TriBsyn™ group, despite its higher bioavailability.
“The TriBsyn™ clinical trial results clearly
showed the elimination of paresthesia and an increased
pharmacokinetic efficiency, confirming enhanced delivery and
exceptional bioavailability,” said Ken Wolf, President and COO of
Natural Alternatives International. “With its advanced Hydro Oleo
technology and carnosine-boosting effects, TriBsyn™ provides
scientifically proven claims to improve muscle vitality, muscle
working capacity, and cognitive performance. It truly sets a new
standard in beta-alanine supplementation and helps fill the gap for
healthy aging and wellness solutions—especially for the active
aging population, GLP-1 users, and those with plant-based
diets.”
About CarnoSyn® Brands:
CarnoSyn® Brands features three clinically studied, patented
and patent pending ingredients available exclusively from Natural
Alternatives International, Inc.: CarnoSyn® instant release
beta-alanine powder, SR CarnoSyn® sustained release
beta-alanine tablets, and TriBsyn™ powder. In 2019, CarnoSyn®
beta-alanine successfully obtained NDI status from the FDA and
received Self-Affirmed GRAS (Generally Recognized as Safe) status.
SR CarnoSyn®, an advanced delivery form of CarnoSyn®, received GRAS
affirmation in 2017. The new “paresthesia-free” TriBsyn™ powder
allows NAI to broaden their product offerings within the dietary
supplement category, medical food and other fortified food
products. To learn more about CarnoSyn® and SR CarnoSyn® in sports
nutrition and wellness, visit www.carnosyn.com and
www.srcarnosyn.com. For more information about our latest
innovation, TriBsyn™, visit www.tribsyn.com.
About NAI:NAI, headquartered in
Carlsbad, California, is a leading formulator, manufacturer and
marketer of nutritional supplements and provides strategic
partnering services to its customers. NAI’s comprehensive
partnership approach offers a wide range of innovative nutritional
products and services to clients including scientific research,
proprietary ingredients, customer-specific nutritional product
formulation, product testing and evaluation, marketing management
and support, packaging and delivery system design, regulatory
review, and international product registration assistance. For more
information about NAI, please visit www.nai-online.com.
Contact:
Renee Michaelson
Director of Global Marketing
NAI/CarnoSyn® Brands
info@nai-online.com
Grafico Azioni Natural Alternatives (NASDAQ:NAII)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Natural Alternatives (NASDAQ:NAII)
Storico
Da Mar 2024 a Mar 2025